A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Trial Profile

A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Estradiol/progesterone (Primary)
  • Indications Vasomotor symptoms
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REPLENISH
  • Sponsors TherapeuticsMD
  • Most Recent Events

    • 14 Oct 2017 Results of a substudy assessing effect of TX-001HR on quality of life in menopausal women with vasomotor symptoms presented at the North American Menopause Society 2017 Annual Meeting
    • 14 Oct 2017 Results assessing effects of tx-001hr on uterine bleeding rates in menopausal women with vasomotor symptoms, were presented at the North American Menopause Society 2017 Annual Meeting.
    • 14 Oct 2017 Results assessing the Medical Outcomes Study-Sleep (MOS-Sleep) questionnaire in Menopausal Women with Vasomotor Symptoms treated with TX-001HR, were of presented at the North American Menopause Society 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top